Literature DB >> 31196496

Disappearing liver metastases: A systematic review of the current evidence.

Diamantis I Tsilimigras1, Ioannis Ntanasis-Stathopoulos2, Anghela Z Paredes1, Dimitrios Moris1, Maria Gavriatopoulou2, Jordan M Cloyd1, Timothy M Pawlik3.   

Abstract

Advances in systemic chemotherapy have resulted in a significant increase in the reported response rates of colorectal liver metastases (CRLM) over time. Although radiologic response is usually prognostic of favorable outcomes, complete shrinkage of CRLM after chemotherapy, namely "disappearing liver metastases" (DLMs) poses significant therapeutic dilemmas. A systematic review of the literature was conducted to evaluate the existing evidence on the imaging and management of patients with DLMs using the PubMed (Medline), Embase and Cochrane library through December 21st, 2018. The following algorithm was used: "(disappearing OR vanishing OR missing OR (residual tiny)) AND ((liver OR hepatic) AND (metastasis OR metastases OR metastatic OR secondary))." From the 225 records retrieved, 15 studies were finally deemed eligible. A total of 479 patients with DLMs with a median age of 59.5 years (range, 30-83) were identified. Median number of DLM per patient ranged from 1 to 8.8. Median size of LMs prior to chemotherapy was 1.07 cm (range 0.3-3.5). The systemic treatment used to achieve DLMs included systemic chemotherapy alone (only 2 studies) or in combination with targeted agents (11 studies). The median number of chemotherapy cycles in the included studies was 7.8 (range 6-12). Identified factors predisposing to the development of DLM were small size (<2 cm), increased number of treatment cycles, oxaliplatin-based therapy, increased number of CRLM (≥3) and synchronous CRLM. Baseline and preoperative MRI with iv contrast showed the highest sensitivity for DLM detection. Fiducial placement facilitated pre- and intra-operative identification of DLM. Although resection of DLM decreased the local recurrence risk, there was no clearly demonstrated survival benefit after resecting all sites of disappearing lesions. Future randomized clinical trials are highly encouraged to provide strict, evidence-based recommendations for the treatment of patients with DLM.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disappearing; Liver metastases; Management; Missing; Vanishing

Mesh:

Year:  2019        PMID: 31196496     DOI: 10.1016/j.suronc.2019.02.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  8 in total

1.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 2.  Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging.

Authors:  Dow-Mu Koh; Ahmed Ba-Ssalamah; Giuseppe Brancatelli; Ghaneh Fananapazir; M Isabel Fiel; Satoshi Goshima; Sheng-Hong Ju; Nikolaos Kartalis; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; Max Seidensticker; Claude B Sirlin; Cher Heng Tan; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Bachir Taouli
Journal:  Eur Radiol       Date:  2021-02-01       Impact factor: 5.315

3.  What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?

Authors:  Qichen Chen; Xingchen Li; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Hong Zhao; Jianqiang Cai
Journal:  Ann Transl Med       Date:  2021-01

4.  Development of a Margin Determination Framework for Tumor-Tracking Radiation Therapy With Intraoperatively Implanted Fiducial Markers.

Authors:  Jihun Kim; Min Cheol Han; Jee Suk Chang; Chae-Seon Hong; Kyung Hwan Kim; Hwa Kyung Byun; Ryeong Hwang Park; Woong Sub Koom; Seong Yong Park; Jin Sung Kim
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

5.  The Influence of Radiological "Disappearing Lesions" on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy.

Authors:  Zhi-Yang Song; Dong Yang; Yang Liu; Yong Cheng
Journal:  Gastroenterol Res Pract       Date:  2022-02-22       Impact factor: 2.260

6.  The dilemma of the disappeared colorectal liver metastasis: systematic review of reviews and evidence gap map.

Authors:  Ahmed Nassar; Sorin Cimpean; Amir Abdelhamid; Robert P Jones; Roger Wahba; Guido Fiorentini; Luca Aldrighetti; Catherine Teh; Ruslan Alikhanov; John Hammond; Michael Silva; Areeg Abdelmabod; Stephanie Truant; Alessandro Ferrero; Christian Sturesson; Irfan Ahmed; Mudassar Ghazanfar; Nobuyuki Takemura; Timothy M Pawlik; Mohamed Bekheit
Journal:  BJS Open       Date:  2022-05-02

Review 7.  Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer.

Authors:  Naoko Sanuki; Atsuya Takeda; Yuichiro Tsurugai; Takahisa Eriguchi
Journal:  Jpn J Radiol       Date:  2022-07-20       Impact factor: 2.701

Review 8.  Colorectal liver metastases: Current management and future perspectives.

Authors:  Jack Martin; Angelica Petrillo; Elizabeth C Smyth; Nadeem Shaida; Samir Khwaja; H K Cheow; Adam Duckworth; Paula Heister; Raaj Praseedom; Asif Jah; Anita Balakrishnan; Simon Harper; Siong Liau; Vasilis Kosmoliaptsis; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2020-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.